Several potential biomarkers may indicate whether patients with bipolar disorder may have high-recurrence disease with a cycle length that progressively shortens, according to Erik Smedler, MD, PhD, of the department of psychiatry and neurochemistry at Gothenburg (Sweden) University.
For the analysis, published in, A total of 745 patients had serum samples available; assays for 203 different protein biomarkers were performed on those samples.
The investigators clustered patients according to frequency – with low-frequency recurrence defined as a maximum of one inpatient episode per year – and by cycle length – with sensitized patients having progressively shorter periods between inpatient episodes. No difference in biomarkers or clinical features were seen between high- and low-frequency recurrence patients, but sensitized patients were significantly more ill and were more likely to be treated with antidepressants.
In addition, in a specific cohort of patients who were both sensitized and had a high recurrence rate (at least five inpatient episodes), four proteins were expressed at a significantly lower level than that of nonsensitized patients:, , placenta growth factor, and . Sensitization also was associated with a single nucleotide polymorphism near the calcium channel gene .
“These results suggest the potential for translational research aimed at preventive actions,” the investigators wrote.
The authors reported that they had no conflicts of interest.
SOURCE: Smedler E et al. Eur Neuropsychopharmacol. 2019 Aug 1. .